Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients

Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients

Abstract Introduction Cancer patients are frail individuals, thus the prevention of SARS‐CoV‐2 infection is essential. To date, vaccination is the most effective tool to prevent COVID‐19. In a previous study, we evaluated the immunogenicity of two doses of mRNA‐based vaccines (BNT162b2 or mRNA‐1273)...

Full description

Bibliographic Details
Main Authors: Maria Silvia Cona, Agostino Riva, Davide Dalu, Arianna Gabrieli, Cinzia Fasola, Giuseppe Lipari, Giacomo Pozza, Eliana Rulli, Francesca Galli, Lorenzo Ruggieri, Elsa Masedu, Gaia Parma, Davide Chizzoniti, Anna Gambaro, Sabrina Ferrario, Maria Antista, Matteo De Monte, Maciej S. Tarkowski, Nicla La Verde
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.5968

Internet

https://doi.org/10.1002/cam4.5968

Similar Items